KOD
Price
$33.80
Change
+$1.38 (+4.26%)
Updated
Sep 22 closing price
Capitalization
2.06B
50 days until earnings call
Intraday BUY SELL Signals
NTLA
Price
$12.69
Change
+$0.47 (+3.85%)
Updated
Sep 22 closing price
Capitalization
1.7B
43 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KOD vs NTLA

KOD vs NTLA Comparison Chart in %
View a ticker or compare two or three
VS
KOD vs. NTLA commentary
Sep 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KOD is a Hold and NTLA is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
KOD vs NTLA: Fundamental Ratings
KOD
NTLA
OUTLOOK RATING
1..100
5162
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3774
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (26) in the Biotechnology industry is somewhat better than the same rating for KOD (73). This means that NTLA’s stock grew somewhat faster than KOD’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as KOD (100). This means that NTLA’s stock grew similarly to KOD’s over the last 12 months.

NTLA's SMR Rating (98) in the Biotechnology industry is in the same range as KOD (100). This means that NTLA’s stock grew similarly to KOD’s over the last 12 months.

KOD's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for NTLA (74). This means that KOD’s stock grew somewhat faster than NTLA’s over the last 12 months.

KOD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NTLA (100). This means that KOD’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KODNTLA
RSI
ODDS (%)
Bullish Trend 3 days ago
83%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 6 days ago
78%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
85%
Bullish Trend 7 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 13 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
79%
Aroon
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
80%
COMPARISON
Comparison
Sep 23, 2026
Stock price -- (KOD: $32.42 vs. NTLA: $12.22)
Brand notoriety: KOD and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KOD: 97% vs. NTLA: 96%
Market capitalization -- KOD: $2.06B vs. NTLA: $1.7B
KOD [@Biotechnology] is valued at $2.06B. NTLA’s [@Biotechnology] market capitalization is $1.7B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $128.84B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KOD’s FA Score shows that 0 FA rating(s) are green while NTLA’s FA Score has 1 green FA rating(s).

  • KOD’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, both KOD and NTLA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KOD’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 6 bullish TA indicator(s).

  • KOD’s TA Score: 4 bullish, 5 bearish.
  • NTLA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than KOD.

Price Growth

KOD (@Biotechnology) experienced а -2.17% price change this week, while NTLA (@Biotechnology) price change was +2.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +27.63%. For the same industry, the average monthly price growth was -6.27%, and the average quarterly price growth was +7.77%.

Reported Earning Dates

KOD is expected to report earnings on Nov 12, 2026.

NTLA is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (+27.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
KOD
Daily Signal:
Gain/Loss:
NTLA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JEMA64.051.71
+2.75%
JPMorgan ActiveBuilders Emerging Markets Equity ETF (JEMA)
SNAV39.270.62
+1.60%
Mohr Sector Nav ETF (SNAV)
KCAI33.670.35
+1.06%
KraneShares China Alpha Index ETF (KCAI)
BRW6.16-0.01
-0.16%
Saba Capital Income & Opportunities Fund
BILT26.56-0.10
-0.36%
iShares Infrastructure Active ETF (BILT)